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an immunocompetent patient: a unique case
Mycobacterium arupense, a slow-growing Mycobacterium, was
ﬁrst isolated from clinical samples in 2006 by Cloud et al.1 and in
water by another team.2 Two cases of tenosynovitis have recently
been reported.3,4 We report here the ﬁrst case of osteomyelitis of
the wrist caused by M. arupense following a penetrating injury to
the hand.
In December 2008, a 35-year-old patient without any signiﬁ-
cant medical history presented with progressive swelling and pain
of the left wrist. Eight months earlier, he had cut the ﬂexor tendons
of his left hand with a glass ﬁlled with mud. An X-ray of the wrist
showed a narrow joint space and two cortical erosions. Echography
revealed an abscess extending to the dorsal face of the wrist. A
synovectomy was performed. Both site cultures for common
bacteria and Mycobacterium were negative. Pathological exami-
nation revealed granulomatous inﬂammation with Langhans giant
cells. Because of the progressive pain in the wrist, a corticosteroid
injection was performed, but did not alleviate the pain.
In May 2010, an X-ray of the wrist showed multiple erosions. An
arthrodesis was performed. M. arupense was identiﬁed by sequenc-
ing of hsp65 and 16S rRNA genes and on culture. The patient then
received clarithromycin (1000 mg daily), rifabutin (300 mg daily),
and ethambutol (1000 mg daily). Rifabutin was discontinued after 2
weeks because of liver disorders. The patient was treated
with clarithromycin–ciproﬂoxacin (1500 mg/day) for 12 months.Table 1
Characteristics of 4 patients with infections due to Mycobacterium arupense
Case Age (years),
gender
Number of months
with symptoms
prior to diagnosis
Co-morbid conditions Risk fac
Tsai et al.3 54, F 7 Diabetes mellitus Injury 
Senda et al.4 68, M 5 Arterial hypertension Cortico
injectio
Neonakis
et al.5
62, M 2 Kidney neoplasm,
hypertension
None 
Our case 35, M 8 None Cortico
injectio
injury
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respectively, as part of the initial regimen. His condition improved.
The arthrodesis was consolidated.
The clinical signiﬁcance of M. arupense is controversial. Only
a few cases have been reported in the literature.3–5 The
characteristics of these patients are listed in Table 1. In most
cases, there was a predisposing factor: corticosteroid injection
or trauma. The optimal therapy for M. arupense osteomyelitis is
not well established in the literature. Data available on
antimicrobial susceptibility are limited. Among eight isolates
studied by Cloud et al.,1 all were susceptible to rifabutin
(minimum inhibitory concentration (MIC) 0.12–0.5 mg/ml) and
ethambutol (MIC 0.5–1 mg/ml). All isolates except one (MIC
64 mg/ml) were susceptible to clarithromycin (MIC 0.5–4.2 mg/
ml). Variable in vitro activities were found for amikacin,
streptomycin, rifampin, cotrimoxazole, and new antibiotic
agents (e.g., linezolid, moxiﬂoxacin, and gatiﬂoxacin). Resistance
to isoniazid was found (MIC >32 mg/ml). In our patient,
although susceptibility was intermediate (MIC 2 mg/ml), high
doses of ciproﬂoxacin were used to prevent the emergence of
resistance, in addition to the initial regimen.
In conclusion, an environmental Mycobacterium should be
suspected when trauma occurs in a patient with progressive pain
and swelling. Identiﬁcation of atypical mycobacteria is crucial,
since not all of them are susceptible to all antituberculous agents.
The prevention of resistance requires the association of various
antituberculous agents.tors Infected site Treatment Duration,
months
Outcome
Tenosynovitis of
the hand
Clarithromycin,
moxiﬂoxacin,
ethambutol, rifabutin
6 Improvement
steroid
n
Tenosynovitis of
the hand
Rifampin, ethambutol 14 Improvement
Lung Clarithromycin,
levoﬂoxacin
? Improvement
steroid
n,
Bone Clarithromycin,
ciproﬂoxacin,
ethambutol, amikacin
12 Improvement
ses. Published by Elsevier Ltd. All rights reserved.
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